Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sunitinib with or without bevacizumab in first-line metastatic renal cell carcinoma was terminated; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Sutent (sunitinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2009-04-10